GYKI-47261 dihydrochloride is a selective AMPA receptor antagonist, administered orally, and exhibits competitive activity with an IC 50 of 2.5 μM. It displays a wide range of anticonvulsive effects and demonstrates neuroprotective properties. Additionally, GYKI-47261 dihydrochloride is a potent inducer of CYP2E1.

GYKI-47261 dihydrochloride, administered intravenously at 6 mg/kg, demonstrates an anti-ischemic effect in a rat model of transient focal ischemia. When given orally, it effectively reduces tremors induced by oxotremorine in male CD1 mice, with an ED50 of 16.8 mg/kg. Additionally, an intraperitoneal dose of 20 mg/kg in male C57 black mice (weighing 23-30 g) counteracts the dopamine depletion caused by MPTP, showing a reversal in the reduced striatal concentrations.